Jingxuan Zhang

Title: Innovations of Jingxuan Zhang in Biopharmaceuticals

Introduction

Jingxuan Zhang is a notable inventor based in Beijing, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of drug targets for the treatment of epithelial tumors. His innovative work has the potential to impact cancer diagnosis and therapy.

Latest Patents

Jingxuan Zhang holds a patent titled "IgG epitope and applications thereof as a drug target." This patent describes an IgG epitope that is derived from the C1 domain of non-B cell-derived IgG. The epitope features an N-glycosylated sialic acid modification at the Asn162 site, which is crucial for its antigen functions. The invention highlights the applications of this IgG epitope as a drug target for preparing drugs aimed at diagnosing and treating epithelial tumors. Furthermore, the research indicates that the sialylation of the Asn162 site is essential for its function as a drug target, with sialyltransferase ST3GAL4 identified as a potential target for tumor therapeutic drugs. Additionally, integrin β4 is co-expressed and co-localized with IgG containing the epitope, suggesting that IgG can serve as a marker for auxiliary detection of epithelial tumors.

Career Highlights

Jingxuan Zhang is associated with Beijing Sig Biopharmaceutical Technology Co., Ltd., where he continues to advance his research and innovations in the biopharmaceutical sector. His work is characterized by a strong focus on the molecular mechanisms underlying tumor biology and therapeutic interventions.

Collaborations

Jingxuan Zhang collaborates with several professionals in his field, including Xiaoyan Qiu and Jingshu Tang. These collaborations enhance the research efforts and contribute to the development of innovative solutions in biopharmaceuticals.

Conclusion

Jingxuan Zhang's contributions to the field of biopharmaceuticals, particularly through his patent on IgG epitopes, demonstrate his commitment to advancing cancer treatment and diagnosis. His work is paving the way for new therapeutic strategies in the fight against epithelial tumors.